Historically, high-sensitivity diagnostic testing for many common diseases consisted of sending samples to an offsite laboratory and potentially waiting hours or days before results were attained and shared with the treating clinician.

In recent years, however, rapid digital immunoassays (DIAs) have been developed to address this risk and inefficiency. ID NOW™, a DIA diagnostic device with a small footprint, allows providers in private practice, urgent care, and other outpatient settings to quickly diagnose influenza A and B, RSV, and strep A with high sensitivity at the site of patient presentation. Having access to reliable, rapid influenza diagnostic tools (RIDTs) at the point of patient care is essential for minimizing the spread of infection, addressing antibiotic overuse, and providing optimal care at the earliest opportunity.


Norman Moore, PhD
Director of Scientific Affairs, Infectious Diseases – Abbott